Recombinant Human Coagulation factor XII (F12), Truncated

Cat.No	ACP00996	Target Name	F12
Form	Liquid or Lyophilized powder	Expression System	E.coli
Expression Range	20-372aa	Mol Weight	43.3 kDa
Protein Length	Partial	Purity	Greater than 85% as determined by SDS-PAGE.
Storage Buffer	5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Cat.No

ACP00996

Target Name

F12

Form

Liquid or Lyophilized powder

Expression System

E.coli

Expression Range

20-372aa

Mol Weight

43.3 kDa

Protein Length

Partial

Purity

Greater than 85% as determined by SDS-PAGE.

Storage Buffer

5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Target Species	Human	Uniprot ID	P00748

Background Information

Uniprot Id

P00748
Target Species

Human
Target Name

F12
Target Full Name

Coagulation factor XII
Target Function

Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then trypsin cleaves it to beta-factor XIIa. Alpha-factor XIIa activates factor XI to factor XIa.
Target Involvement

Factor XII deficiency (FA12D); Hereditary angioedema 3 (HAE3)
Target Subcellular Location

Secreted.
Target Protein Families

Peptidase S1 family
Target Research Area

Cardiovascular
Target Synonyms

Factor XII; Beta factor XIIa part 1; Beta factor XIIa part 2; Coagulation factor XII; Coagulation factor XIIa heavy chain; Coagulation factor XIIa light chain; F12; F12 deficiency; FA12_HUMAN; Factor XII deficiency; HAE3; HAEX; HAF; HAF deficiency; Hageman factor
Target Background

This gene encodes coagulation factor XII which circulates in blood as a zymogen. This single chain zymogen is converted to a two-chain serine protease with an heavy chain (alpha-factor XIIa) and a light chain. The heavy chain contains two fibronectin-type domains, two epidermal growth factor (EGF)-like domains, a kringle domain and a proline-rich domain, whereas the light chain contains only a catalytic domain. On activation, further cleavages takes place in the heavy chain, resulting in the production of beta-factor XIIa light chain and the alpha-factor XIIa light chain becomes beta-factor XIIa heavy chain. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then to beta-factor XIIa. The active factor XIIa participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. It activates coagulation factors VII and XI. Defects in this gene do not cause any clinical symptoms and the sole effect is that whole-blood clotting time is prolonged.

Recombinant Human Coagulation factor XII (F12), Truncated

Specifications

Immunogen Information

Inquire Recombinant Human Coagulation factor XII (F12), Truncated Now

Related Products